Mal-PEG2-VCP-Eribulin is a drug-linker conjugate composed of Mal-PEG2-VCP (an ADC linker) and Eribulin (a highly potent mitotic/tubulin inhibitor used a warhead in ADC). Eribulin (E7389; E-7389; trade name Halaven) is microtubule targeting agent (MTA) that has been approved for use in the treatment of metastatic breast cancer. Mal-PEG2-VCP-Eribulin is used in the construction of antibody drug conjugates-ADC.

纯度：≥98%

CAS：2130869-18-8